Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity

Autor: Stacey Tannenbaum, Martin den Adel, Walter Krauwinkel, John Meijer, Adriana Hollestein‐Havelaar, Frank Verheggen, Donald Newgreen

Publikováno v: Pharmacology Research & Perspectives, Vol 8, Iss 6, Pp n/a-n/a (2020)

Abstract The aim of this investigation was to characterize and compare the pharmacokinetics (PK) of the antimuscarinic drug solifenacin in pediatric patients with overactive bladder (OAB) or neurogenic detrusor overactivity (NDO) utilizing data from

Externí odkaz: https://doaj.org/article/85e5b4f3221a4d9cb0b201cd02faf4f2

Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical Trial

Autor: Newgreen, Donald, Bosman, Brigitte, Hollestein-Havelaar, Adriana, Dahler, Ellen, Besuyen, Robin, Sawyer, Will, Bolduc, Stéphane, Rittig, Søren

Publikováno v: In European Urology March 2017 71(3):483-490

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder

Autor: Ellen Dahler, Robin Besuyen, Søren Rittig, Brigitte Bosman, Robert Snijder, Stéphane Bolduc, Donald Newgreen, Adriana Hollestein-Havelaar, Will Sawyer

Publikováno v: Newgreen, D, Bosman, B, Hollestein-Havelaar, A, Dahler, E, Besuyen, R, Snijder, R, Sawyer, W, Rittig, S & Bolduc, S 2017, ' Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder ', Journal of Urology, vol. 198, no. 4, pp. 928-936 . https://doi.org/10.1016/j.juro.2017.05.038

We evaluated the long-term safety and efficacy of once daily oral solifenacin suspension in children (5 to less than 12 years old) and adolescents (12 to less than 18 years old) with overactive bladder.We conducted a 40-week, open label extension of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1bbf364430c4d83082372787285829c
https://doi.org/10.1016/j.juro.2017.05.038

610 Solifenacin in children and adolescents with over-active bladder: Results of a Phase 3 clinical trial

Autor: Newgreen, D., Bosman, B., Sawyer, W., Hollestein-Havelaar, A., Besuyen, R., Dahler, E., Bolduc, S., Rittig, S.

Publikováno v: In European Urology Supplements April 2015 14(2):e610